Featured Article| Volume 19, ISSUE 3, 104514, March 2023

Essential Thrombocythemia

Published:January 27, 2023DOI:


      • Essential thrombocythemia is a rare myeloproliferative disease
      • This article reviews implications for the primary care provider and treatment regimens.


      Essential thrombocythemia, a myeloproliferative neoplasm (MPN), causes excessive clonal platelet production of poorly formed platelets. Medical management includes treatment to reduce symptoms and exacerbations of thrombosis and hemorrhage. Care in the primary care setting includes awareness, diagnosis, and co-management for this complicated disease.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The Journal for Nurse Practitioners
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Jinna S.
        • Khandhar P.B.
        Hydroxyurea Toxicity.
        StatPearls, 2022 (Updated May 1, 2022)
        • National Comprehensive Cancer Network
        Myeloproliferative Neoplasms.
        (Version 3.2022)
        • Verstovsek S.
        • Yu J.
        • Scherber R.
        • Verma S.
        • Dieyi C.
        • Chen C.
        • Parasuraman S.
        Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States.
        Leuk Lymphoma. 2022; 63: 694-702
      1. Swerdlow S.H. Campo E. Harris N.L. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, 2008
        • Tefferi A.
        • Barbui T.
        Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management.
        Am J Hematol. 2020; 95: 1599-1613
        • Meier B.
        • Burton J.H.
        Myeloproliferative disorders.
        Hematol Oncol Clin North Am. 2017; 31: 1029-1044
        • Lussana F.
        • Carobbio A.
        • Salmoiraghi S.
        • et al.
        Driver mutations (jak2v617f, mplw515l/k or calr), pentraxin-3 and c-reactive protein in essential thrombocythemia and polycythemia vera.
        J Hematol Oncol. 2017; 10: 54
        • Arber D.A.
        • Orazi A.
        • Hasserjian R.
        • et al.
        The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.
        Blood. 2016; 127: 2391-2405
        • Pemmaraju N.
        • Gerds A.
        • Yu J.
        • et al.
        Thrombotic events and mortality risk in patients with newly diagnosed polycythemia vera or essential thrombocythemia.
        Leuk Res. 2022; 115 (106809): 2022
        • Tefferi A.
        • Vannucchi A.M.
        • Barbui T.
        Essential thrombocythemia treatment algorithm 2018.
        Blood Cancer J. 2018; 8: 2
        • Marchioli R.
        • Finazzi G.
        • Specchia G.
        • et al.
        Cardiovascular events and intensity of treatment in polycythemia vera.
        N Engl J Med. 2013; 368: 22-33
        • Wellstein A.
        • Giaccone G.
        • Atkins M.B.
        • Sausville E.A.
        Cytotoxic Drugs.
        in: Brunton L.L. Hilal-Dandan R. Knollmann B.C. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 13th ed. McGraw Hill, 2017
        • Gisslinger H.
        • Gotic M.
        • Holowiecki J.
        • et al.
        Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial.
        Blood. 2013; 121: 1720-1728
        • Harrison C.N.
        • Campbell P.J.
        • Buck G.
        • et al.
        Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.
        N Engl J Med. 2005; 353: 33-45
        • Padrnos L.
        • Scherber R.
        • Geyer H.
        • et al.
        Depressive symptoms and myeloproliferative neoplasms: understanding the confounding factor in a complex condition.
        Cancer Med. 2020; 9: 8301-8309
        • Rossau H.K.
        • Kjerholt M.
        • Brochmann N.
        • Tang L.H.
        • Dieperink K.B.
        Daily living and rehabilitation needs in patients and caregivers affected by myeloproliferative neoplasms (MPN): a qualitative study.
        J Clin Nurs. 2022; 31: 909-921
        • Mesa R.
        • Miller C.B.
        • Thyne M.
        • et al.
        Myeloproliferative neoplasms (MPNs) have a significant impact on patients’ overall health and productivity: the MPN Landmark survey.
        BMC Cancer. 2016; 16: 167
        • Mesa R.A.
        • Miller C.B.
        • Thyne M.
        • et al.
        Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: findings from the MPN Landmark survey.
        Cancer. 2017; 123: 449-458
        • Palandri F.
        • Ross D.
        • Cochrane T.
        • et al.
        P1033: a phase 2 study of the LSD1 inhibitor IMG-7289 (BOMEDEMSTAT) for the treatment of essential thrombocythemia (ET).
        HemaSphere. 2022; 6: 923-924
        • Jutzi J.S.
        • Kleppe M.
        • Dias J.
        • et al.
        LSD1 inhibition prolongs survival in mouse models of MPN by ç.
        Hemasphere. 2018; 2: e54
        • Verstovsek S.
        • Komatsu N.
        • Gill H.
        • et al.
        SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia.
        Future Oncol. 2022; 18 (doi:10.2217/fon-2022-0596): 2999-3009
        • Handlos Grauslund J.
        • Holmström M.O.
        • Jørgensen N.G.
        • et al.
        Therapeutic cancer vaccination with a peptide derived from the calreticulin exon 9 mutations induces strong cellular immune responses in patients with calr-mutant chronic myeloproliferative neoplasms.
        Front Oncol. 2021; 11 (637420): 637420


      Ruth Madden Foreman, DNP, FNP-BC, is an assistant professor of nursing, Graduate Nurse Practitioner Programs, College of Health & Wellness, Carlow University, Pittsburgh, PA, and can be contacted at [email protected]


      Richard Brzustowicz, MLIS, is an instruction and outreach librarian, Carlow University, Pittsburgh, PA.